ArticlePharmacoEconomics2023
The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice.
Article in PharmacoEconomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 45 citations in OpenAlex.
- Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models.Therapeutic innovation & regulatory science · 2026Article
- Beyond scarring: a next-generation vision for pulmonary fibrosis management.Molecular biology reports · 2026Review
- In-hospital costs of malignant brain tumor surgery: A systematic review and quality assessment.Neuro-oncology practice · 2026Review
- Towards a Multi-sectoral Approach to Population Health: A Scoping Review of Cross-sectoral Evaluations of Health Interventions.Applied health economics and health policy · 2026Review
- Diagnostic value of MRI for posttreatment surveillance of early-stage (I-II) glottic larynx cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Cost-effectiveness of RefluxStop for gastroesophageal reflux disease: analysis from an Italian healthcare perspective.BMC gastroenterology · 2026Article
- Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches.Developing world bioethics · 2026Article
- Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- The value of health and well-being from a societal perspective: A willingness to pay experiment in the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Disease-modifying treatments in paroxysmal nocturnal hemoglobinuria: a systematic review of economic evaluations.Cost effectiveness and resource allocation : C/E · 2025Review
- Comment on current management of esophagojejunostomy leakage after total gastrectomy.Journal of minimally invasive surgery · 2025Article
- Effective and Efficient Rehabilitation. What Works Best for Persons With SCI During (Sub)Acute Phase of Rehabilitation?Archives of rehabilitation research and clinical translation · 2025Article
- The contribution of health and health systems to other sustainable development goals. An overview of the evidence on co-benefits.Health policy (Amsterdam, Netherlands) · 2025Review
- The economic burden of brucellosis in Western Iran.Tropical medicine and health · 2025Article
- Cost-effectiveness protocol for treating adult HIV-infected patients with Kaposi sarcoma in resource-limited settings: a phase III, randomized, open-label, non-inferiority study of paclitaxel and pegylated liposomal doxorubicin.Cost effectiveness and resource allocation : C/E · 2025Article
- The PICO Puzzle: Can Public Data Predict EU HTA Expectations for All EU Countries?Journal of market access & health policy · 2025Article
- Establishing a Research Agenda for Physiotherapy in Portugal: A Delphi Study.Physiotherapy research international : the journal for researchers and clinicians in physical therapy · 2025Article
- A proposition of hybrid healthcare pathway to screen and diagnose obstructive sleep apnea: exploratory analysis of retrospective observational data.Sleep & breathing = Schlaf & Atmung · 2025Observational
- Benefits beyond health in the willingness to pay for a quality-adjusted life-year.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- The Future of Arthroplasty in the Spine.International journal of spine surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A cost-effectiveness analysis has become an important method to inform allocation decisions and reimbursement of new technologies in healthcare. A cost-effectiveness analysis requires a threshold to which the cost effectiveness of a new intervention can be compared. In principle, the threshold ought to reflect opportunity costs of reimbursing a new technology. In this paper, we contrast the practical use of this threshold within a CEA with its theoretical underpinnings. We argue that several assumptions behind the theoretical models underlying this threshold are violated in practice. This implies that a simple application of the decision rules of CEA using a single estimate of the threshold does not necessarily improve population health or societal welfare. Conceptual differences regarding the interpretation of the threshold, widely varying estimates of its value, and an inconsistent use within and outside the healthcare sector are important challenges in informing policy makers on optimal reimbursement decision and setting appropriate healthcare budgets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.